Skip to main content
Equibles
BCYC logo

BCYC · Bicycle Therapeutics PLC · Metrics

Track BCYC — free

Use BCYC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCYC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.86 +0.03 (+0.78%) At close · Sep 11
Rebalance outlook locked
Market Cap
$270.17M
Shares
69.99M

BCYC metrics

68 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.86
Market cap
$270.17M

Price action

20 metrics
Price change (1W)
-10.2%
Price change (30D)
-1.0%
Price change (3M)
-4.7%
Price change (6M)
-19.2%
Price change (YTD)
-45.5%
Price change (1Y)
-45.0%
Trailing year
Price change (5Y)
-90.4%
52-week high
$8.87
52-week low
$3.83
Change from 52-week high
-56.5%
Change from 52-week low
+0.8%
Annualized volatility
51.6%
Annualized volatility (3M)
38.0%
Beta
1.5
RSI (14D)
38.7
Price vs SMA 50
-6.6%
Price vs SMA 200
-24.9%
Avg volume (3M)
440,036
Relative volume
1.4
Average dollar volume
$1.80M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
69.99M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.4×
reciprocal yield 22.7%
P / book
0.5
reciprocal yield 188.9%
FCF yield
-77.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-70.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
35.5×
reciprocal yield 2.8%
EV / revenue historical average (5Y)
37.2×
reciprocal yield 2.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-10-30

Profitability

9 metrics
Gross margin
—
Operating margin
-343.6%
Trailing 12 months
Net margin
-311.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$210.30M
Net income (TTM)
−$190.41M
Trailing 12 months
Diluted EPS (TTM)
$-2.73
FCF margin
-340.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.31

Growth

11 metrics
Revenue growth YoY
-78.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$61.20M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.8%
Year over year · more shares
Revenue CAGR (3Y)
+71.2%
Revenue CAGR (5Y)
+47.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-37.3%
Return on assets
-31.4%
Debt / equity
—
Current ratio
12.1
EBITDA (TTM)
−$204.98M
Free cash flow (TTM)
−$208.28M
Quick ratio
12.1
Interest coverage
-1,089.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$510.05M
Total assets
$606.58M
Total debt
$30.91M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$206.05M
Capital expenditures (TTM)
$2.23M
R&D (TTM)
$200.26M
SG&A (TTM)
—
Stock compensation (TTM)
$33.76M
R&D / revenue
327.2%
Stock compensation / revenue
55.2%

Ownership (13F)

3 metrics
13F filers
103
13F filer change QoQ
+5
Institutional ownership
53.9%

Short interest

3 metrics
Short interest
4.7%
Latest settlement · 13.8 days to cover
Days to cover
13.8d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$60,461
Insider-sentiment score
36 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1761612 CUSIP 088786108 13F (30d) 48 filings 48 filers Visit website Investor relations